Casopitant (zunrisa) Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Casopitant (INNTooltip International Nonproprietary Name), former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting. It was under development by GlaxoSmithKline. In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary. However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.   Wikipedia

Chemistry

  • SMILES: CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1
  • InChIKey: XGGTZCKQRWXCHW-WMTVXVAQSA-N
  • Mol. Mass: 616.62
  • ALogP: 6.65
  • ChEMBL Molecules:
    casopitant  
    casopitant mesylate  
More Chemistry

Pharmacology

Alternative names

casopitant | casopitant mesilate | casopitant mesylate | gw679769 | gw-679769 | zunrisa

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Depression (Phase 2)

Depressive Disorder, Major (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Dyspepsia (Phase 2)

Nausea (Phase 3)

Neoplasms (Phase 3)

Phobia, Social (Phase 1)

Postoperative Nausea and Vomiting (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 2)

Urinary Bladder, Overactive (Phase 2)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 29
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue